In This Issue:

- Letter from the President
- DAD Journal Corner
- CPDD 2022 Travel Awards Winners
- Member Spotlight: Dr. Michelle Doyle
- ECMC Member Spotlight: Dr. Jerry Cochran
- CPDD Mentorship Program Update
- CPDD Committee Reports
CPDD EXECUTIVE COMMITTEE

President
Amy C. Janes, Ph.D.

President-Elect
Deborah Hasin, Ph.D.

Treasurer
Jack Bergman, Ph.D.

Past-President
William Stoops, Ph.D.

Public Policy Officer
Sandra Comer, Ph.D.

CPDD BOARD OF DIRECTORS
Sudie Back, Ph.D.
Jack Bergman, Ph.D.
Qiana Brown, M.P.H., M.S.W., Ph.D., LCSW
Sandra Comer, Ph.D.
Kelly Dunn, M.B.A., Ph.D.
Francesca Filbey, Ph.D.
Albert Garcia-Romeu, M.A., Ph.D.
Cassandra Gipson-Reichardt, Ph.D.
Angela Heads, Ph.D.
Jermaine Jones, Ph.D.
Wendy Lynch, Ph.D.
Silvia Martins, M.D.
Angela Moreland, Ph.D.
Marco Pravetoni, Ph.D.
James Rowlett, Ph.D.
Dace Svikis, Ph.D.
Michael Taffe, Ph.D.
Erin Winstanley, Ph.D.

CPDD EX OFFICIO

Rules Chair
Charles Gorodetzky, M.D., Ph.D.

Executive Officer
Jesse Howard

EDITORS
Maria Parker, M.P.H., M.S., Ph.D.

CPDD COMMUNICATIONS COMMITTEE
Bethea (Annie) Kleykamp, Ph.D. Chair
Daniel Fuster, M.D., Ph.D.
Rachel Gicquelais, M.P.H., Ph.D.
Jodi Gilman, Ph.D.
Jillian Hardee, Ph.D.
Barrett Montgomery, B.S.
Jacques Nguyen, Ph.D.
Maria Parker, M.P.H., M.S., Ph.D.
Tasha Perdue, Ph.D.
Frank Schwebel, Ph.D.

Want to contribute or advertise in Newsline?
Email info@cpdd.org
Dear friends and colleagues,

As the Northern Hemisphere begins to settle in for winter, CPDD is only beginning to heat up and I couldn’t be prouder to be your President. Having wrapped up our 84th annual conference and a return to an in-person meeting this June, I am excited to begin showcasing the future of CPDD.

I want to express my sincere and heartfelt congratulations to our outgoing president, Dr. Bill Stoops. Transitioning back to an in-person meeting after a two-year hiatus was no minor task and this top-notch event required countless hours of planning from Dr. Stoops, the CPDD Executive Committee, Board of Directors, Program Committee, and PMG team. Not only did the College deliver a premier event, but CPDD made great strides in the implementation of our strategic plan. Under Dr. Stoop’s direction as the Long-Range Planning Committee Chair, I am excited to see what lies next for the College as we enter our 94th year.

I would be remiss if the College didn’t recognize the dedication of our outgoing Program Committee Chair, Dr. Kelly Dunn. Her devotion to the College and goal to deliver the latest research left us all in awe. The Program Committee and Dr. Dunn deserve the highest accolades for ensuring the success of our return to in-person meetings. Now, we welcome Dr. Kevin Freeman as the new Program Committee Chair. Based on the symposia, mini-symposia, forum, and workshop submissions received during the open call, we are sure to have another fantastic meeting to look forward to and are in good hands under Dr. Freeman’s leadership.

In addition to welcoming Dr. Freeman as the new Program Committee Chair, we also welcome Dr. Deborah Hasin as our new President-Elect. Dr. Hasin’s first task will be to lead the 2022-2023 CPDD Nominating Committee. The Committee is comprised of distinguished members of our community, including Drs. Omayma Alshaarawy, Michael Bardo, Jermaine Jones, and Mark Smith. Nominations are open through Tuesday, December 27. Considering nominating a fellow CPDD member for President-Elect, Treasurer or Board member. Click Here for more information.

The CPDD Executive Committee, Program Committee, Board of Directors, and PMG team are already busy planning for the 85th Annual Scientific Meeting taking place at the Sheraton Denver Downtown June 17-21, 2023. This year, CPDD eliminated the need for sponsor letters both for membership and abstracts. We hope this change will allow more individuals to participate. It is important to note that there is a very large conference taking place while we are in Denver. It will be very important to book your hotel accommodations early as we anticipate selling out. The hotel block will open soon.

2022 has been a remarkable year for the College. The Board of Directors is very proud of the entire CPDD community and look forward to continuing to advance the field of substance use disorder research. We continue to advocate for our critical research, reduce barriers for engaging with CPDD, and create an engaging annual meeting that supports a range of research topics. I look forward to seeing each of you at next year’s meeting and hearing from you this year as your President.

Healthy regards,

Amy Janes, PhD
CPDD President
2023 CPDD Annual Meeting

Oral & Poster Abstract Submissions

Make your Oral and Poster submissions for CPDD's 85th Annual Meeting from October 10th through December 16th.

SUBMIT NOW
Multiple Substance Use, Inflammation, and Cardiac Stretch in Women Living with HIV


This longitudinal study followed 74 community-recruited unsheltered and unstably housed women living with HIV (WLWH) monthly for six months. Our goal was to understand the linkages between drug use, inflammation, and NT-proBNP, a biomarker of cardiac stretch and heart failure. Among multiple cardiovascular risk factors and >30 drug metabolites studied, cannabis use had a negative/protective association with NT-pro BNP, while sTNFR2 (an inflammatory analyte) had a positive association. Cannabis use was not significantly associated with sTNFR2. Whether results suggest that cardiovascular pathways associated with cannabis use mitigate cardiac stress independent of inflammation among WLWH who use multiple substances merits further investigation.

Modeling HIV Transmission Among Persons Who Inject Drugs (PWID) at the “End of the HIV Epidemic” and during the COVID-19 Pandemic

Don Des Jarlais, Georgiy Bobashev, Jonathan Feelemyer, Courtney McKnight

*Drug Alcohol Depend.* 2022 Sept 1; 109573 doi.org/10.1016/j.drugalcdep.2022.109573

To explore injecting risk and HIV incidence when incidence was extremely low in New York City (NYC) (2012-2019), we developed an Agent-Based Model (ABM) to simulate sharing injecting equipment and HIV incidence. Data for the model were taken from the “Risk Factors” study, a long-running study of PWID in NYC. Model output was highly consistent with empirical studies of HIV incidence. Key determinants of low incidence were minimizing transmission behavior of HIV seropositive persons and confining syringe sharing by HIV seronegative persons within small stable groups. Potential COVID-19 disruptions increased the probability of an outbreak from 0.03 to 0.25.

Prevalence of Mental Disorders Among People with Opioid Use Disorder: A Systematic Review and Meta-Analysis

Thomas Santo, Jr., Gabrielle Campbell, Natasa Gisev, Daniel Martino-Burke, Jack Wilson, Samantha Colledge-Frisby, Brodie Clark, Lucy Thi Tran, Louisa Degenhardt

*Drug Alcohol Depend.* 2022 Sept 1; 109551 doi.org/10.1016/j.drugalcdep.2022.109551

We conducted a systematic review and meta-analysis to estimate the prevalence of specific mental disorders among people with OUD. Compared to the general population, people with OUD had far higher rates of depression (36%), anti-social personality disorder (34%), anxiety (29%), attention-deficit/hyperactivity disorder (21%), post-traumatic stress disorder (PTSD; 18%), borderline personality disorder (18%), and bipolar disorder (9%). Women with OUD had elevated rates of depression, anxiety, and PTSD. Our findings emphasize the need for access to mental disorder treatment among people with OUD. Results can inform treatment services for people with OUD, including subpopulations with distinct treatment needs.
Multi-Chemokine Receptor Antagonist RAP-103 Inhibits Opioid-Derived Respiratory Depression, Reduces Opioid Reinforcement and Physical Dependence, and Normalizes Opioid-Induced Dysregulation of Mesolimbic Chemokine Receptors in Rats

Angela R. Bongiovanni, Pingwei Zhao, Saadet Inan, Sonita Wiah, Aryan Shekarabi, Daniel J. Farkas, Mia N. Watson, Mathieu E. Wimmer, Michael R. Ruff, Scott M. Rawls
Drug Alcohol Depend. 2022 Sept 1; 109556 doi.org/10.1016/j.drugalcdep.2022.109556

New therapeutics with no abuse liability that decrease opioid tolerance and dependence without exacerbating opioid-induced respiratory depression are a priority for the 2 million Americans with an opioid use disorder (OUD). Chemokines are inflammatory cytokines that influence therapeutic and adverse opioid effects. Our rat studies showed that RAP-103, a safe orally active peptide that blocks multiple chemokine receptors (CCR2, CCR5, CCR8), reduced heroin intake, motivation to take heroin, morphine physical dependence and morphine-induced respiratory depression. We demonstrate that non-addictive multi-chemokine receptor antagonist RAP-103, reduces opioid dependence and limits physical dependence, which could benefit patients initiating Medication Assisted Therapies for OUDs.
Save the Date
85th Annual Meeting
Registration is OPEN
DENVER, CO | June 17 - 21, 2023
2022 Travel Award recipients received complimentary registration to the 2022 Annual Meeting and are eligible to apply for the same award in the future (excluding the Holtzman and Primm-Singleton).

**8th Annual Steve G. Holtzman Travel Award for Preclinical Investigators**
- Bernard Johnson, MS, Wake Forest School of Medicine

**CPDD International Award**
- Abdelazim Assi, B.A., Ch.B., Assiut University
- Tara Rezapour, Ph.D., Department of Cognitive Psychology, Institute for Cognitive Science Studies (ICSS)

**FORCE Award**
- Kirsten Smith, Ph.D., National Institute on Drug Abuse, Intramural Research Program
- Nina Christie, M.A., University of Southern California
- Tanya Saraiya, Ph.D., Medical University of South Carolina

**Primm-Singleton Minority Travel Award**
- Elizabeth Stinson, B.S., University of Wisconsin-Milwaukee
- James-Angelo Suarez, M.P.H., University of South Florida
- Joshua Zamora, B.S., University of Texas Medical Branch
- Sina Kianersi, D.V.M., Indiana University Bloomington School of Public Health
- Sitara Weerakoon, B.A., M.P.H., UTHealth SPH

**CPDD Early Career Investigator Awards**
- Alyssa Harlow, Ph.D., University of Southern California
- Camille Cioffi, Ph.D., University of Oregon
- Carlos Zamarripa, Ph.D., Johns Hopkins University School of Medicine, Department of Psychiatry
- Carmen Lim, M.Sc., National Centre for Youth Substance Use Research, The University of Queensland, Australia
- Christina LaValley, B.S., Wake Forest School of Medicine
- Dae Hee Han, Ph.D., University of Southern California
- Daicia Allen, Ph.D., University of California, Los Angeles
- Danielle Smith, M.P.H., Roswell Park Comprehensive Cancer Center
- Deborah Luessen, Ph.D., Vanderbilt University
- Elizabeth Austin, M.P.H., University of Washington
- Elzbieta Wiedbusch, B.S., University of South Florida
- Emmanuelle Baillet, M.Sc., University of Bordeaux
- Joao De Aquino, M.D., Yale University School of Medicine
- Jonathan Stoltman, Ph.D., Opioid Policy Institute
- Judy Hong, Ph.D., The University of Texas Health Science Center at Houston
- Juhan Lee, Ph.D., Yale University School of Medicine
- Kathryn Biernacki, Ph.D., UBHC Department of Psychiatry, Brain Health Institute at Rutgers University – New Brunswick
- Kevin Xu, M.P.H., M.D., Washington University School of Medicine
- Madeline Frost, M.P.H., University of Washington School of Public Health, Department of Health Systems & Population Health
- Matthew Myers, M.P.H., Michigan State University College of Human Medicine
- Megan Cooke, Ph.D., Harvard Medical School, Massachusetts General Hospital
- Nina Pocuca, Ph.D., R.N., University of Montreal
- Philip Spechler, Ph.D., Laureate Institute for Brain Research
- Rachel Barry, B.A., Palo Alto University
- Rachel French, Ph.D., National Clinician Scholars Program, University of Pennsylvania
- Sarah Cousins, M.P.H., Semel Institute for Neuroscience, Human Behavior at UCLA
- Thomas Brothers, M.D., Dalhousie University Faculty of Medicine
- Vitor Tardelli, M.S., M.D., Universidade Federal de Sao Paulo/Centre for Addiction and Mental Health, University of Toronto
- Yitong Xin, M.B.A., M.S.W., The Ohio State University
- Yuhui Zhu, Ph.D., Semel Institute – UCLA
NIDA Women & Sex/Gender Junior Investigator Travel Awards

- Amy Johnson, Ph.D., Vanderbilt University
- Catherine Moore, Ph.D., Johns Hopkins University School of Medicine
- Devika Bhatia, M.D., University of Colorado School of Medicine
- Eleanor Towers, B.S., University of Virginia
- Erin Berthold, B.S., University of Florida
- Gregory Hard, MHS, R.N., Pennsylvania State University
- Hannah Apsley, B.S., Pennsylvania State University
- Jessica Kulak, M.P.H., M.S., Ph.D., University at Buffalo
- Joy Gray, Pennsylvania State University
- Karen Alexander, Ph.D., R.N., Friends Research Institute
- Keisha Smith, Ph.D., Yale University School of Medicine, Department of Psychiatry
- Megan Marziali, B.Sc., M.P.H., Columbia University Medical Center
- Michelle Eglovitch, M.P.H., Virginia Commonwealth University
- Morgan Sotzen, B.S., Michigan State University
- Nina Pocuca, Ph.D., University of Montreal
- Orrin Ware, M.P.H., M.S.W., Ph.D., Johns Hopkins University School of Medicine
- Paola Mattey Mora, M.P.H., Indiana University
- Raymond Moody, Ph.D., Columbia University, Mailman School of Public Health
- Samara Mayer, M.P.H., BC Centre on Substance Use and University of British Columbia
- Taylor Crouch, Ph.D., Virginia Commonwealth University School of Medicine
- Alice Ely, Ph.D., Perelman School of Medicine University of Pennsylvania
- Nicole Fitzgerald, B.A., University of Florida
- Brianna George, B.A., Wake Forest School of Medicine
- Priscila Goncalves, Ph.D., Columbia University
- Sarah Gutkind, M.S., Columbia University
- Zachary Mannes, M.P.H., Ph.D., Columbia University, Mailman School of Public Health
- Nathaniel Moxley-Kelly, M.Sc., University of Vermont
- Alexandra Palmisano, Ph.D., Yale University School of Medicine
- Justin Strickland, Ph.D., Johns Hopkins University School of Medicine
- Andre B. Toussaint, M.A., Temple University
- Neil Varshneya, B.S., M.S., Ph.D., Johns Hopkins University School of Medicine
- Noel Vest, Ph.D., Stanford University School of Medicine
- Alison Wakeford, Ph.D., Harvard Medical School McLean Hospital
- Heather Webber, Ph.D., University of Texas Health Science Center

NIDA Directors Travel Awards

- Angel Algarin, M.P.H., Ph.D., University of California San Diego
- Trent Bullock, M.A., Lewis Katz School of Medicine at Temple University
- Danielle Davis, Ph.D., Yale University School of Medicine
- Teresa DeAtley, M.P.H., Brown University School of Public Health
- Michelle Doyle, B.S., University of Texas Health Science Center at San Antonio
Introducing the CSAM-SMCA 2022 Keynote Speakers

Bridging National Policies and Local Realities: Can We Coordinate for the Future?

Director of Program Planning and Operations, Mental Health and Addictions, Health PEI

What’s Next with the Opioid Crisis? Emerging from the Fog of the War on People Who Use Drugs

Peter A. Allard School of Law, University of British Columbia

CSAM-SMCA 2022 Scientific Conference and Annual Meeting
Sex differences in addiction research studies are well-noted at the behavioral level, both in humans and animal models of substance use disorders. For example, women progress more rapidly from casual drug use to a substance use disorder. Likewise, cocaine acquisition in rodents tends to be faster in female rats than in male rats. These findings strengthen the argument for including male and female subjects in addiction research studies. While sex differences have been well characterized in some stimulants, sex differences in 3,4-methylenedioxypyrovalerone (MDPV) are not as well characterized. MDPV, a monoamine uptake inhibitor, is part of a family of synthetic cathinones also known as "bath salts." MDPV and other bath salts are a public health concern due to their high abuse liability and marketing as the cheaper option to stimulants such as cocaine. Interestingly, a "high-responder" phenotype has been observed in subset of male rats that self-administer MDPV, and this phenotype carries over to other stimulants. However, some evidence suggested a history of cocaine self-administration may prevent the development of the phenotype. Understanding whether sex plays into the high-responder phenotype is of particular interest to Michelle Doyle, a Ph.D. student in laboratory of Dr. Greg Collins in the Department of Pharmacology at the University of Texas Health Science Center at San Antonio.

In a recent study (Doyle et al. 2021 Psychopharmacology) Michelle Doyle and her colleagues examined whether the high-responder phenotype also developed in female rats self-administering MDPV, as well as, further characterized whether a history of cocaine self-administration protected against the development of this phenotype. Female rats were trained to self-administer MDPV, cocaine, or food pellets. The rats that initially responded for cocaine or food pellets were later switched to MDPV. Rats were classified as high-responders if more than 20% of their responses were made during time-out periods. Dose-response curves for MDPV were generated under a fixed ratio schedule of reinforcement to measure reinforcing potency, then the rats were switched to a progressive ratio (PR) schedule of reinforcement to measure the reinforcing effectiveness of MDPV. Half of the rats self-administering MDPV were characterized as high-responders, whereas only a single rat self-administering cocaine and no rats self-administering food pellets were characterized as high-responders. When all rats were switched to self-administering MDPV, more than half of the rats with a history of responding for food pellets developed the high-responder phenotype. However, no rats with a history of cocaine self-administration developed the high-responder phenotype during MDPV self-administration. There were no differences in the reinforcing potency or effectiveness of MDPV between the rats with different drug histories. This study demonstrated that a subset of female rats develops a high-responder phenotype following MDPV self-administration. Furthermore, protection against the development of the high-responder phenotype cannot be afforded simply to a history of operant behaviors, rather a history of cocaine responding is important for the protective effects. Michelle and colleagues noted that the outcomes of these studies were similar to earlier studies using male rats under the same conditions, suggesting that there may not be sex differences in MDPV self-administration or the development of the high-responder phenotype. Michelle Doyle’s introduction to psychopharmacology began as an undergraduate student at Tufts University, working in the laboratory of Dr. Klaus Miczek. With Dr. Miczek, Michelle first became involved with addiction research when she studied the intersection between stress and cocaine self-administration. She followed her interest in this line of research to the McLean Hospital and the Harvard Medical School where she worked as a technician in the laboratory of Dr. Jack Bergman, under the direction of Dr. Rajeev Desai. Michelle Doyle is entering her final year of her Ph.D. program and will soon be looking for postdoctoral research opportunities. She is particularly interested in studying treatments for substance-use disorders as well as identifying the processes that factor into substance-use disorders. Michelle has been a member-in-training of CPDD since 2018. In addition to many awards won over her time as a graduate student, Michelle was awarded the NIDA Director’s Travel Award and the NIDA Women and Sex/Gender Junior Investigator Travel Award to attend the annual CPDD meetings in 2021 and 2020, respectively. She also won the Excellence in Preclinical Work by a Pre-Doctoral Researcher Award at the Early Career Research Presentation Competition at the 2021 meeting.
Day-to-Day work
What issue has been persistent/hard to resolve in your area of expertise?
The major area of focus I have been concentrating on has been integrating opioid misuse or treatment services into non-addiction specialty care settings. Examples of this are the work I have done with obstetrics and pharmacy services.

What is a rising issue in your area of expertise?
A pressing area of focus is how to better integrate non-prescribers into the process for medication treatment of opioid use disorder (MOUD). For instance, we have been working closely with large community pharmacy chains to train pharmacists and related staff to help provide care for patients with risky opioid use. Our goal is to establish a model of care in which pharmacists can independently manage patients with opioid use disorder.

Long-term career
In the short-term, we all want to get grants and publish papers, but what do you/did you consider as your long-term career goals? (e.g. tenure, editor positions, directorship positions?)
Honestly, I have had personal experiences with family and friends suffering from addiction. I can see the faces of these loved ones in each of the studies I have done. Throughout my career, I have wanted to come up with evidence-based solutions to problems that could have helped my loved ones.

To what do you attribute your success?
Hard work and to keep showing up. I don’t consider myself the most talented or brilliant person. But, I go to work every day, make sacrifices to be productive, and keep at it despite failures. I also believe the work in which I am involved is important—changing lives, which I believe makes good karma.

Work/life balance
Any tips? The work never ends, so what boundaries do you have in place to protect your personal time and your sanity?
I only work part of the day on Saturdays, and not on Sundays. I keep that time as set apart for my family, service, and rest (rest being not so much sleep, but changing my focus to other important aspects of my life).

In your experience, when is a better time to start a family? Should it be after you graduate, after completion of a post-doctoral fellowship, after completion of few years of first faculty position, or perhaps some other time?
The sooner the better I think. Having a family is an intense motivator to be productive and not waste time. A family also is an immense source of support during the highs and lows—and helps put into perspective what is most important in life.

Overcoming adversity
Was there a time in your career that you found particularly difficult, and how did you get through it?
Yes, I have worked in organizations that are not functioning well and that made serious leadership and administrative mistakes—that have directly impacted faculty and staff. These have been the most difficult. To get through those times, I strive to keep a positive attitude and hoped that, over time, things would eventually work out for a net positive change. Also, in these difficult times, reaching out to mentors and trusted leaders for support and trusting my gut have been key.

What do you think are the most common adversities that new and established professionals are facing in workplace? What is your advice/what are your potential solutions for overcome these adversities?
I think the most important thing one can do is find a good team of mentors, peers, and staff. Going it alone is unnecessarily difficult. Surrounding yourself with people who you enjoy being around and who support you is key; they can help carry your burdens—and you theirs.

Advice for Young Investigators
What advice would you give to a new grad student, a new postdoc, or a new investigator?
Be humble, collaborative, and develop grit.

What would you recommend to people who have a fear of missing out on all of the great conferences and presentations? How many conferences a year should one strive to attend?
I wouldn’t worry too much about missing out on conferences or conference presentations. My advice is to attend the sessions that are most relevant to you and where you can meet possible collaborators. I strive to attend at least 2 conferences a year, which I think is a good number for students and new investigators. Do your best to stay engaged while balancing the many responsibilities that we have in our lives.
CALL FOR ABSTRACTS

Opens October 17th
Closes December 16th

Submit your Poster/Oral abstracts for #CPDD23.

SUBMIT NOW
The CPDD Mentorship Program is an initiative coordinated by the Early Career Member Committee (ECMC). The program aims to connect early career researchers (i.e., predoctoral fellows, postdoctoral fellows, medical residents) with more experienced researchers in their field to discuss topics such as career development, research ideas, and future goals. Mentor-mentee pairs are matched based on multiple factors, including research interests, career field, and individual requests. Mentees do not need to be CPDD members to participate. Mentorship pairs often choose to connect in-person at one of the many networking opportunities scheduled during the CPDD conference; however, participants met virtually during the 2020 and 2021 conferences and may continue to choose to do so. The 2022 CPDD Mentorship Program was a great success with 58 mentees paired with 54 mentors. Due to increased interest in this program each year, we ask mentors if they would be willing to provide mentorship for 1 or 2 mentees. Because of the generosity of mentors and their willingness to spend time mentoring, all mentees were paired with a mentor this year!

Prior to assigning mentors, mentees are encouraged to prepare their CV, as well as questions they would like to ask their mentor match. Once mentor/mentee matches are created, mentees are encouraged to initiate contact and scheduling the meeting, and to research their mentor’s work, if they are unfamiliar.

Results from a follow up survey of mentors/mentees indicated that the 2022 program was well received. Most survey respondents (62%) reported meeting in-person at the conference, while 31% reported meeting virtually and/or connecting over email. The majority of respondents (38%) indicated that they met with their mentor/mentee for over an hour, while 35% reported meeting for approximately 30-60 minutes, and 19% reported meeting for approximately 15-30 minutes. Approximately 75% of survey respondents felt their mentor/mentee was a good match. Concrete outcomes from the meeting for included planned future networking and ideas for collaboration and funding.

These results suggest that the CPDD Mentorship Program continues to be a successful ECMC initiative. The flexibility of the mentors and mentees provides options to connect virtually or in-person. The ECMC is always looking for feedback on how to improve and expand this program. If there are Newsline readers interested in providing additional feedback, please feel free to contact Maya Zegel (mzegel@central.uh.edu) who facilitated this year’s program.
TRAVEL AWARDS SUBMISSIONS OPEN NOW

Opens October 17th, 2022
Closes December 16th, 2022

SUBMIT NOW
Animals in Research Committee
The mission of the Animals in Research Committee of CPDD is to address issues related to the conduct of biomedical research using laboratory animals. The purpose of such research is to understand, treat, and prevent disease. In particular, the members of CPDD are interested in understanding drug addiction. Research using animals has the promise of elucidating the basic mechanisms that lead to addiction, evaluating therapeutic drugs for the treatment of addiction, and developing strategies to prevent addiction.

The Committee’s Animal Forum, “The 3Rs Concept of “Replacement”: Future Tools or Political Strategy?”, is being prepared for submission to the Annual 2023 Meeting in Denver. The goals of this Forum are to provide information to the membership regarding recent controversies and political implications associated with alternatives to animals in research. Recognizing that animal alternatives are an active research area; we also will provide a case study in how a state-of-the-art in silico methodology was developed and is implemented. Our speakers will be Dr. Robert Hester and Dr. James Rowlett (University of Mississippi Medical Center).

The last Member Spotlight submissions were published in 2021: Dr. Jacques Nguyen from UC-San Diego (submitted by former member Sally Huskinson), and Dr. Michelle Doyle, UTHSC-San Antonio (submitted by Rachel Altshuler). Importantly, Dr. Altshuler’s submission was for a MIT, which was approved by the Executive Committee.

The committee will publish at least two additional articles for the membership spotlight series in the Newsline and CPDD website for 2022-2023. Our chair participated in 2022 Advocacy Day, and at least three past and present members (Berro, Garcia, Serafine) have indicated they will participate in 2023.

Awards Committee
Greetings from the CPDD Awards for Excellence Committee! Our committee is privileged to administer the Nathan B. Eddy Memorial Award, the Marian W. Fischman Lectureship Award for An Outstanding Woman Scientist, the Mentorship Award, the Joseph Cochin Young Investigator Award, the J. Michael Morrison Award and the Innovator Award. We are pleased to again congratulate the winners of the 2022 CPDD Awards for Excellence (note that the J. Michael Morrison Award was not offered this year).

- Nathan B. Eddy Memorial Award: Stephen Higgins, Ph.D., University of Vermont
- Marian W. Fischman Lectureship Award: Laura Bierut, M.D., Washington University School of Medicine
- Mentorship Award: Anthony Riley, Ph.D., American University
- Joseph Cochin Young Investigator Award: Andrew Huhn, M.B.A., Ph.D., Johns Hopkins University School of Medicine
- Innovator Award: Linda Dwoskin, Ph.D., University of Kentucky

CPDD and the Awards for Excellence Committee are proud to announce the new CPDD Mary Jeanne Kreek Underserved Populations Award. Dr. Kreek, along with her colleagues Vincent Dole and Marie Nyswander, had a leading role in the development and implementation of methadone. Her pioneering work fostered dignity and respect in the treatment of patients with heroin addiction, and she was a long-time proponent of diversity, equity and inclusion (DEI) research. This award was established to recognize scientists who have focused their research efforts on improving the lives of individuals from underserved populations with substance use problems.

Nominees from all career stages, including those engaged in preclinical as well as clinical research, who prioritize DEI in their work, will be considered.

Our committee would also like to remind the membership that we are committed to a confidential, yet transparent, review process. The committee members are required to disclose actual or perceived conflicts of interest with any of the nominees—those with conflicts do not participate in the review process for a given award. Committee members not in conflict are provided the confidential materials for each nominee, and asked to give preliminary scores, which are then used to guide the review discussion. Merit is the primary criterion, but diversity is encouraged and embraced. We would also like to remind everyone of some important nomination rules: individuals can only nominate one person for an award but are permitted to submit nominations for more than one award, the same person cannot be nominated for more than one award in the same year, and Awards for Excellence Committee members are not allowed to be nominated for an award. Thank you for keeping these restrictions in mind when considering potential nominees for next year’s awards.
I am honored to continue to serve as the Chair for the Awards for Excellence Committee and look forward to working with the Committee and the College to recognize the best and brightest of our members in the coming years. Please consider nominating deserving colleagues for one or more of the CPDD Awards for Excellence next year, and/or making award donations.

**Communications Committee**
The Communications Committee has been busy expanding its work around the dissemination of substance use research including a range of educational and social media efforts.

One effort included a new and improved Media Forum at the 2022 annual conference which was hosted in collaboration with the Opioid Policy Institute and titled, "Harnessing Your Expertise: CPDD Media Training with Reporting on Addiction". Attendees learned best practices in science journalism, including pitching stories to editors and increasing the reach of their research findings. Work is now underway to incorporate lessons learned from this year’s forum into an updated format for 2023.

In addition, the committee continues to support ongoing projects including the production of bi-annual CPDD Newsline and CPDD member submissions to the News and Views section of *Drug and Alcohol Dependence*. News and Views submissions can be made by any CPDD member and should highlight new advances in substance use research. The submissions are peer-reviewed and can include up to 2,500 words.

New committee efforts currently underway include a new submission process that will allow members to share recommendations for posts shared to the CPDD twitter. The posts will profile cutting-edge, recent research on substance use and addiction. In tandem, we are preparing to launch a speaker series that will profile the work of CPDD members using a brief video format shared on the CPDD website. These videos are meant to profile the work of early career members, as well as research focused on racism and the health of minoritized groups that have been underrepresented in substance use research. In addition, we have a subcommittee that is developing a webinar that will provide education and expert views on addressing stigma in substance use research and treatment. Topics being considered include stigmatizing language and stigma-focused research initiatives, as well as representation of people with lived experience and their experience with stigma. The Communications Committee have also implemented a new Share Your Work section to CPDD’s website, for members to share projects and publications that can then be shared via social media.

If members are interested in learning more about these new initiatives and/or contributing, please reach out to Dr. Annie Kleykamp (akleykamp@gmail.com).

**Early Career Member Committee**
The Early Career Member Committee (ECMC) is dedicated to serving the needs of early career investigators involved with CPDD. We have conducted a variety of initiatives over the past several months aimed at benefiting our undergraduate, graduate, post-doc, and other early career investigators and are excited to continue with exciting programming.

At the annual CPDD conference, we conducted the annual "Navigating a Career in Addiction Science" workshop in which researchers from a variety of career paths, including academia, the private sector, and government shared about their career trajectory, tips for early career investigators, and recommendations about career paths. ECMC has successfully put on this workshop for several years and were excited for another well-received iteration of this workshop. We plan to continue this workshop for future years.

In addition, we also hosted two additional programs for early career members at the CPDD conference: the ECMC Poster Competition and the Annual Mentorship Program. The ECMC Poster Competition is in its second year and while it is a relatively new program, it also holds a lot of promise! We were able to award two predoctoral fellows and two postdoctoral fellows who had terrific posters with a cash prize! We also had several terrific honorable mention posters and look forward to continuing the competition. The mentorship program, a longstanding program from the ECMC was also successfully implemented in-person after two years of being a remote program.

We’re excited to welcome several new members to the committee for the 2022-2023 term and hope to continue with our ongoing conference programming, as well as new and innovative programming aimed at serving early career members!
Human Research Committee
The mission of the Human Research Committee is to identify and recommend actions on issues relating to the ethics and safety of drug use research with humans, methodological issues relating to design and measurement in studies with humans, and scientific issues of interest to clinical researchers and CPDD in general.

To that end, the committee presented its annual forum in CPDD 2022 meeting on ‘Resuming Research on Substance Use Disorders after Lifting COVID-19 Distancing Measures: Challenges and Opportunities’. Topics included addressing provider and system-level barriers to opioid use disorder treatment via telehealth (Dr. Ursula Myers); the association between COVID-19 and alcohol use among a trauma-exposed sample (Dr. Elizabeth Santa Ana); the challenges and opportunities of online-only trials in the post-COVID era (Dr. Steven Ondersma); and screening, brief intervention, and referral for vaccine for researchers engaged in drug use research (Dr. Maureen Reynolds). The forum elicited important discussions and provided attendees with different perspectives and best practices to conduct drug use research in the era of global pandemics.

The committee also requested feedback from CPDD members on previous forums, and topics of interest for future discussion/action. Responses are currently recorded to guide future efforts by the Human Research Committee.

International Committee
The International Committee (IC) is excited to welcome three new members: Thiago Fidalgo from the Universidade Federal de São Paulo, Brazil, Suzaily Wahab from the Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Malaysia, and Erin Winstanley from West Virginia University, USA. We would like to express our sincere gratitude to Francesca Filbey for her service as the IC chair, her significant contributions to the IC, and positive impacts on the international CPDD community over the past three years.

The IC is dedicated to promoting substance use research and treatment at the international level by recognizing promising scientists, assisting the NIDA International Program, and assisting CPDD members in other countries in the scientific study of substance use disorders.

To that end, the IC is committed to creating a dedicated international networking zone at future CPDD meetings to provide a space for initiating international research collaborations and learning about opportunities in the US for international researchers. We aim to invite former NIDA Humphrey and INVEST fellows to share their experiences and provide guidance to international researchers, particularly during the early stages of their careers.

The IC is also planning to submit a workshop for the 2023 CPDD meeting, following the success of the workshops hosted by the IC in the previous two years. This workshop will focus on innovative interventions and methodological approaches utilized internationally. We hope that researchers based in the US will draw inspiration from these novel and unique tools, and that international researchers can learn from their colleagues’ experiences in contexts similar to their own (e.g., in low- and middle-income countries or rural areas).

Finally, we are excited to continue our partnership with the NIDA International Program and we look forward to working with the new leadership team, Jennifer Hobin and Lindsey Friend!

Long-Range Planning Committee
The Long-Range Planning Committee continues with its mission to help CPDD meet its long-term goals and identify new directions the College may want to take. I began my term as Chair of the committee in June 2022 and welcomed two new members: Dr. Jermaine Jones and Dr. Sharon Walsh. Over the next year, we will continue to assist with roll out of the CPDD Strategic Plan (e.g., developing and refining the standard operating procedures of a new Education Committee) and will also continue work begun during my term as President to address NIH racial funding inequities. We welcome any member input on ways that CPDD can better meet its strategic goals! I can be contacted at william.stoops@uky.edu.

Membership Committee
The Membership committee of CPDD continues to work toward our mission, which includes two primary goals/objectives: 1) attend to activities that address recruitment of new members and retention of current members, and 2) review and evaluation of applications for membership in CPDD.

The Membership committee welcomed six new members in June 2022 and said good-bye to several members who have been instrumental in keeping our activities moving forward. We thank the former committee members for their time, which includes the former chair of the Credentials committee, Dr. Kyle Kampman, in addition to the following committee members: August Holtyn, James Mahoney, Eric Strain, Judith Tsui, and George Woody. We welcome our new committee members including: Lisham Ashrafioun, Lawrence Brown, Bradford Fischer, Caitlin Martin, Kelly Peck, and Suzanne Nielsen. And of course, we thank our current
Our committee continues to work to promote membership in the college and to improve processes for interested individuals to obtain membership. Last year, the Membership committee voted to review applications every other month (bi-monthly) moving forward. More frequent review of member applications has been asked for repeatedly by conference attendees and the BOD, and we’re pleased with the new system that we have in place. Additionally, the process for submitting membership applications has been streamlined and improved, and systems are in place for the committee to more easily access application materials, review, and vote on applications. We thank the Parthenon group for making the application submission and review process easier. This change improves the committee’s efficiency and ability to review applications in a timely manner.

There are several areas of growth for our committee and initiatives that we plan to pursue over the next several months and years. First, we plan to review what the committee has done in the past to recruit new members and what can be done moving forward to recruit and encourage more diverse membership in our college. We plan to formalize our membership drives and forge connections with diverse organizations and groups that can spread the word about CPDD. We continue to work closely with the underrepresented populations (URPOP) committee to accomplish our shared goals of improving representation in CPDD. Second, we continue to discuss how we can reduce barriers to membership that may affect the submission of applications and interest in the college. These conversations continue to evolve, and we always look for membership input to determine how best to improve our procedures and processes.

Our committee continues to promote membership in the college and attract new members, but as always, we need your assistance to spread the word about the benefits of CPDD membership within your professional networks. Thus far in 2022, we have recommended approval for 78 new members to the college (45 of which are members-in-training). The number of new members joining the college in 2021 was 107 and in 2020 was 103. We hope to exceed those numbers in 2022. Helping the Membership committee to promote and encourage new member applications is always appreciated!

Program Committee
Greetings CPDD colleagues, the Program Committee extends its thanks to all who participated in our return to an in-person gathering for the 2022 meeting. After two consecutive virtual meetings, we came together in a physical space with the glee of “return to normal”, but also with some trepidation (at least on the planning end) about the degree to which that normal could be obtained. We were not disappointed. The meeting blended traditional content with new twists to enhance the experience. We introduced a special session to highlight collaborative work being conducted between industry and academia under NIDA’s SBIR/STTR mechanism, which we plan to continue on an annual basis. Moreover, we facilitated networking for our junior members who have missed opportunities in recent years due to the absence of in-person gatherings by offering dedicated space and times to gather with senior membership and representatives from NIDA.

Significant enhancements were also introduced to the formatting of presentations. To streamline session flow, oral sessions were reduced to one hour for a total of four talks, and responses from members about this “punchier” format have been overwhelmingly positive. We also incorporated a digital interaction feature for symposia that allowed attendees to post questions in an app during the session to generate crowd-sourced content for a moderated discussion period at the end of the sessions. We plan to continue with these changes, and we are listening to the membership to help guide us with even more innovations for 2023.

We want to acknowledge the service of our committee members who rotated off after the 2022 meeting. They are Drs. Matthew Banks, Diann Gaalema, Jennifer Tidey, and Reagan Wetherill. In addition, we are excited to welcome Drs. Marc Auriacombe, Cecilia Bergeria, Abenaa Jones, Catalina Lopez-Quintero, and Carol Paronis as incoming members to the Program Committee. Finally, we thank our departing Chair, Dr. Kelly Dunn, for her stellar leadership over the past three years. Dr. Dunn led the Program Committee through an unprecedented time that included a rapid pivot to digital content in 2020, an exceptional digital meeting in 2021, and a return to in-person formatting in 2022 that many lauded as one of the top gatherings in memory. Dr. Dunn exhibited great fortitude in her ability to adapt and innovate under all circumstances, and her creative additions (e.g., SBIR/STTR session; streamlined oral sessions) will become hallmarks of our future programming. We are grateful for your leadership, Dr. Dunn!

Travel Awards Committee
The CPDD Travel Awards Committee would like to thank Dr. Ryan Vandrey for his service as chair over the previous term. We also welcome new members Shanna Babaloni, Yatan Pal Singh Balhara, Chuan-Yu Chen, Thiago Fidalgo, Dustin Lee, R. Kathryn McHugh, Ty Schepis, Kristen Smith, Tory Spindle, and Yukikko Washio.

The committee met virtually in September to review standard
operating procedures and to begin preparation for the 2023 meeting. We expect the call for applications for CPDD Early Career Investigator Travel Awards, FORCE Travel Awards, NIDA Director’s Travel Awards, NIDA Women and Sex/Gender Travel Awards, and the Holtzman Travel Award for Preclinical Investigators to go out in late October. Descriptions of and eligibility requirements for these travel awards can be found on the CPDD website: https://cpdd.org/awards/travel-award-descriptions/.

**Underrepresented Populations Committee**

The URPOP committee continues to be busy with a variety of current and new goals resulting from CPDD’s new Long-Range Plan. The committee has rewritten the preamble to its annual DEI survey with the plan of writing a paper based on the results of the survey. The committee presented its first poster based on the results of last year’s DEI survey and the poster was presented on the first poster board during all poster sessions of the 2023 Annual Meeting in Minneapolis. The committee is working on updates to the survey questions and answers and will continue to publish a poster representing the most updated survey results at each year’s annual meeting.

Under the new chair, Dr. Angela Heads URPOP has updated its mission statement to better reflect the goals represented by the new CPDD Long-Range Plan. The committee has conducted a DEI survey among its members and the Board of Directors, asking for information on each individual’s institution DEI initiatives. The committee is currently reviewing the results of the survey to determine new ways to promote DEI within CPDD. Finally, the committee is working on an initiative to provide underrepresented populations who also receive Pell Grants, opportunities for reduced membership and meeting attendance costs.
The College on Problems of Drug Dependence

Strength in Numbers

CPDD Membership
Application Deadlines: November 30th

LEARN MORE